Primary transcripts of the human estrogen receptor (ER) and progesterone receptor (PR) are subject to a number of alternative splicing events resulting in a range of variant messenger ribonucleic acid species in receptor-positive tissues. Despite in vitro demonstrations of a possible role for some of these variants in hormonal sensitivity, the clinical significance of this process is uncertain. In this study the coexpression of variant ER and PR transcripts has been documented by RT-PCR and Southern blot analysis in a series of receptor-positive breast tumors. In 35 ER-positive tumors, a common profile of variant ER transcripts was present, with all tumors containing the ⌬ 2 ER and ⌬ 7 ER, 94% containing the ⌬ 4 ER, and 83% containing the ⌬ 5 ER. In 25 of these cases, which were also PR positive, the most highly expressed PR variants, the ⌬ 4 PR, ⌬ 6 PR, and ⌬ 4/2 PR, a transcript from which a 126-bp portion of PR exon 4 was deleted, were detected in over 90% of the cases. The alternatively spliced ER variants were expressed at higher relative levels than the PR species, which had mean levels of expression less than 10% that of wild-type PR. The most abundant species was the ⌬ 7 ER, which was present at levels ranging from 29 -83% of the wild type. There was no relationship between the level of ⌬ 7 ER in individual tumors and the pattern of expression of the estrogen-responsive proteins PR and pS2. The common profile of alternatively spliced ER and PR transcripts in breast tumors means that this feature cannot be used as a discriminator of hormone responsiveness or other clinical end points. Further, the low level of expression of the majority of variant species calls into question their potential for impacting significantly on receptor function. (J Clin Endocrinol Metab 84: 1370 -1377, 1999 
T HE OVARIAN steroid hormones estrogen and progesterone influence the development and function of the normal human breast and are implicated in the inception and progression of breast cancer. This hormone-responsive character of breast cancer not only gives insight into the essential nature of the disease, but allows a therapeutic opportunity, as it has been known for over a century that manipulation of the endocrine environment of a tumor can induce regression in some circumstances (1, 2) . The effects of estrogen and progesterone in their target tissues are mediated by specific nuclear hormone receptors [estrogen receptor (ER) and progesterone receptor (PR)]. These receptors also mediate the effects of therapeutic endocrine agents in breast cancer, and their presence indicates a greater likelihood of response to this form of treatment (3, 4) . However, the presence of ER and PR is not always accompanied by a response to endocrine agents (3, 4) , and receptor expression may be retained after resistance to this form of treatment is acquired (5, 6) .
The discrepancy between the presence of receptors and the likelihood of a response to endocrine agents in breast cancer has led to speculation that breast tumors may contain forms of ER or PR with aberrant function. To investigate this possibility, the ER has been extensively examined at the messenger ribonucleic acid (RNA) level, and it has emerged that the primary ER transcript in both normal and malignant tissue is commonly subjected to a number of alternative splicing events that give rise to a range of truncated transcripts (7) . Since their discovery, there has been speculation that these transcripts may encode ER variants that are clinically important in breast cancer, and functional correlates of some of these have been examined in vitro. One species in particular, lacking exon 5 of the ER transcript, (⌬ 5 ER), has generated considerable interest, as it has been found to have low level constitutive transcriptional activity (8) , and relative to wild-type ER function, both dominant positive (9) and dominant negative (10) activities have been ascribed to the ⌬ 5 ER in specific experimental circumstances. Dominant negative activity has also been attributed to the exon 7-deleted (⌬ 7 ER) (11), exon 3-deleted (⌬ 3 ER) (12, 13) , and exon 4-deleted (⌬ 4 ER) (14) ER variants in some expression systems. Analogous to ER, the existence of alternatively spliced transcripts of PR has been demonstrated recently in breast tumors (15, 16) , and in vitro functional studies have provided evidence that PR variants lacking exon 6 (⌬ 6 PR) and exons 5 and 6 (⌬ 5ϩ6 ) of the PR sequence may have dominant negative activity relative to that of the wild-type receptor (17) .
Despite intriguing functional data from in vitro experiments, attempts to correlate the expression of alternatively spliced ER transcripts with clinical features of breast tumors have not clarified the role variant receptors may play in hormone resistance or disease progression. In a study by Zhang et al. the presence of multiple, alternatively spliced ER transcripts was documented in a series of 109 primary breast tumors, and no correlation between the presence of these variants and clinicopathological variables or disease recurrence was found (18) . In two small studies, modest increases in the level of the ⌬ 5 ER variant have been reported in breast tumors compared with that in normal breast (19) and in recurrent breast cancer compared with that in primary tumors (20) . The level of this variant was not elevated in tamoxifen-resistant tumors, however (21) , nor was it related to disease-free survival in patients treated with adjuvant tamoxifen (18) . Erenburg et al. have reported that breast tumors express significantly lower levels of the ⌬ 3 ER variant transcript than normal breast specimens and have proposed on the basis of the dominant negative activity of this receptor in vitro that this difference may play a role in the malignant phenotype (13) .
To begin to understand this issue, the broader significance of splicing of receptor transcripts needs to be considered. The question of whether alternative splicing is a general phenomenon in breast tumors and whether tumors that contain alternatively spliced ER transcripts also contain alternatively spliced PR transcripts in particular needs to be addressed. The aim of this study was to document alternatively spliced ER and PR transcripts in a series of breast tumors and to determine whether the coexpression of alternatively spliced ER and PR transcripts was related to receptor function and, hence, hormone sensitivity in breast cancer.
Subjects and Methods

Patient material
Tumor samples were taken from 35 women with primary carcinoma of the breast treated at Westmead Hospital (Sydney, Australia). The patients ranged in age from 42-83 yr (mean, 60.8).
Detection of ER and PR
ER and PR measurements were made as part of the routine pathological assessment of tumors by enzyme immunoassay (EIA) using the Abbott ER EIA and PgR EIA kits (Abbott Laboratories, Diagnostics Division, North Chicago, IL), as previously described (22) . ER or PR values of 15 fmol/mg protein or greater by EIA were deemed positive. The precise quantity of receptors in samples whose ER or PR content was higher than the upper limit of the standard curve was not determined; instead, these were reported as greater than the highest measurable value only. For the purposes of this analysis, this highest value has been used to approximate ER and PR content in such cases. The ER status of tumors was confirmed by immunohistochemical staining of paraffinembedded tumor sections using a mouse monoclonal anti-human ER antibody Dako-ER 1D5 (Dako Corp., Carpinteria, CA) after microwave antigen retrieval.
Detection of pS2
The estrogen-responsive protein pS2 was detected by immunohistochemistry in paraffin-embedded tumor sections. Sections were incubated for 10 min at 37 C in a 0.05% (wt/vol) solution of protease, (Sigma Pronase Protease Type E, Sigma-Aldrich Co., Castle Hill, Australia) before incubation with a polyclonal anti-pS2 antibody, NCL-pS2 (Novocastra Laboratories Ltd., Newcastle-Upon-Tyne, UK), overnight. After blocking with 3% hydrogen peroxide, a secondary biotin-conjugated antirabbit Ig was applied to the sections for a minimum of 30 min, followed by streptavidin-horseradish peroxidase for an additional period of at least 30 min. Diaminobenzidine was used as the chromogen, and the sections were lightly counterstained with hematoxylin before coverslipping. Negative control slides, consisting of sections incubated overnight with diluent only or normal rabbit serum at 1:200 in diluent, rather than the primary antibody were performed, and a case known to give a positive result was included in each staining run.
Semiquantitative analysis of each section was carried out. The number of tumor cells stained positively was counted, and the percentage of cells stained was calculated for each case. Tumor cell counting was facilitated by viewing sections and counting with a video image analysis system (Optimas Corp., Seattle, WA). In accordance with some other reports (21, 23) , tumors with 10% or more of cells staining positively were designated positive.
Extraction of RNA
Frozen tumor tissue stored at Ϫ70 C for up to 6 yr was pulverized in a supercooled vessel, suspended in a guanidinium isothiocyanate solution, and homogenized using a Dounce homogenizer (Kontes Co., Vineland, NJ) and Teflon pestle. Total RNA was extracted by the guanidinium isothiocyanate-cesium chloride method as previously described (24) .
RT-PCR amplification of ER and PR transcripts
Fragments of the ER transcript were amplified by the RT-PCR using the primers indicated in Fig. 1 . Oligonucleotide sequences are given below. Details of the ER sequence are taken from the reports of Greene et al. (25) and Ponglikitmongkol et al. (26) . An EcoRI restriction site was added to the 5Ј-end of some sense primers, and this is indicated in bold type. Sequences for primers ER 1, ER 2 and ER D were taken from the report by Fuqua et al. (27) For each reaction, 200 -600 ng tumor RNA were reverse transcribed by 50 U Moloney murine leukemia virus reverse transcriptase at 37 C for 60 min in a 20-L reaction using the specific antisense primer in the presence of ribonuclease inhibitor and 1 mmol/L deoxy-NTPs. Subsequent amplification of the complementary DNA (cDNA) produced was achieved in a 100-L reaction by addition of the sense primer, MgCl 2 to a final concentration of 1.5 mmol/L, 2.5 U Taq polymerase, and the recommended concentration of Taq reaction buffer supplied by the manufacturer. In each reaction a sample without RNA was included as a negative control. RNA from the breast cancer cell line T47D was in- cluded as a positive control. PCR conditions were optimized for each primer set, and 30 or 40 cycles of amplification were performed, except for the reaction examining exon 7 of ER (see below). Amplification of fragments of the PR transcript by RT-PCR from the same tumors was performed by a similar method, which has previously been described (16) .
Southern blot analysis
Aliquots of each PCR product mix were electrophoresed through agarose gels containing ethidium bromide and were transferred to nylon membranes, (Hybond N ϩ , Amersham, Castle Hill, Australia), using capillary action. Membranes were probed with exon-specific oligonucleotide sequences from ER and PR and PR cDNA, labeled with 32 P. Radioactively labeled membranes were evaluated using a Molecular Dynamics, Inc., PhosphorImager and ImageQuant software (Sunnyvale, CA).
A semiquantitative estimate of alternatively spliced transcript expression was made by comparing the intensities of the variant and wild-type bands on Southern blots as previously described (21, 28) . Levels of the variant transcripts were expressed as a percentage of the wild-type level. Levels of the ⌬ 5 ER reported in Table 1 are derived from the mean results of 2 separate determinations for each tumor. Relative expression of the most abundant variant, the ⌬ 7 ER, was examined in detail. For this reaction, the kinetics of amplification were documented by comparing the intensity of the wild-type and ⌬ 7 ER signals on Southern blot over a range of PCR cycles. These results showed that both products were amplified with similar efficiency, and the ratio of the two products was comparable throughout the reaction (data not shown). Semiquantitative results of the relative expression of ⌬ 7 ER are the mean values from 3 separate RT-PCR reactions for 30 tumors and from 2 reactions for 5 cases. In each case, measurements were made in both the plateau (30 cycles) and linear (19 cycles) phases of amplification.
Subcloning and sequencing
Sequence verification of the ⌬ 7 ER, ⌬ 4 PR, and ⌬ 6 PR variants was performed by subcloning the RT-PCR products into the pGEM-T vector (Promega Corp., Sydney, Australia). The ⌬ 4/2 PR variant was sequenced directly from the RT-PCR product. Sequencing was performed by automated dideoxy chain termination sequencing (373A DNA Sequencing System, Applied Biosystems, Foster City, CA).
Statistical methods
Statistical tests were performed using Abacus Concepts StatView Student software (Abacus Concepts, Inc., Berkeley, CA).
Results
Expression of alternatively spliced variant ER transcripts
Segments of the ER transcript spanning each of exons 2-7 were separately amplified by RT-PCR. Examples of Southern blots from these experiments are shown in Fig. 2 . A region spanning exon 2 was amplified, and a product corresponding in size to the expected 446-bp wild-type ER was seen ( Fig.  2A) . This band hybridized with an oligonucleotide positioned in exon 3 (ER E) on Southern blots, and in addition, a smaller product corresponding in size to an ER transcript lacking exon 2 (⌬ 2 ER) was revealed in all cases. Further evidence of the identity of the variant was derived from an experiment in which a duplicate of one of the Southern blots was probed with an oligonucleotide from the exon 2 ER sequence (ER C), and the smaller band failed to hybridize (not shown).
When the region spanning exon 3 was amplified, a band corresponding to the wild-type ER sequence was seen on agarose gels and on Southern blots probed with an oligonucleotide that binds to exon 4 of ER (ER 1; Fig. 2B ). A smaller band was only faintly seen in some cases. To visualize products more clearly, RT-PCR products from a subset of cases were run on 6% polyacrylamide gels and stained with silver. By this method, a band of approximately the correct size for the exon 3-deleted ER variant (⌬ 3 ER) was seen, which may represent a variant ER transcript, however, the intensity of this band was very low compared with that of wild-type ER (data not shown). It was concluded that the ⌬ 3 ER was not confidently identified in this series, and if present, the level of expression was likely to be very low.
The predicted exon 4-deleted ER transcript (⌬ 4 ER) was seen in addition to wild-type ER on Southern blots probed with an exon 5 ER sequence (ER F2; Fig. 2C ) in 33 of the 35 cases, and when 1 of the blots was stripped and reprobed with an oligonucleotide in exon 4 (ER 1), the variant was not detected (not shown). Primers used in the original description of the exon 5-deleted ER variant (⌬ 5 ER) were used to amplify the ER sequence spanning exon 5 (27) (Fig. 2D) . The ⌬ 5 ER, identified on the basis of its size and differential hybridization to an oligonucleotide probe in exon 4 (ER D) but not one in exon 5 (ER F2; not shown), was detected in 29 of the 35 tumors. Amplification of exon 6 revealed no evidence of an exon 6-deleted variant (⌬ 6 ER) in any of the cases on Southern blots (Fig. 2E) or when a subset was run on acrylamide gels and stained with silver (data not shown).
In all of the ER-positive cases, amplification across exon 7 revealed wild-type and the exon 7-deleted variant (⌬ 7 ER). In contrast to the other variants, the ⌬ 7 ER could be discerned on agarose gels containing ethidium bromide; consistent with this, it was the most intense signal relative to that of the wild type on Southern blots (Fig. 2F) . The variant hybridized with ER sequences from exons 6 (ER 2) and 8 (ER 8.2), but not a probe positioned in exon 7 (ER H) (not shown). The identity of the variant was further proven by subcloning and sequencing of the wild-type and ⌬ 7 ER RT PCR products from two tumors (not shown).
Expression of alternatively spliced PR transcripts
Of the 35 ER-positive tumors examined, 26 were PR positive by EIA. The PR transcript was examined in 25 of these by amplifying 2 fragments by RT-PCR: one spanning exons 2, 3, and 4 and the other spanning exons 5, 6, and 7, (16) . Using this strategy, a number of variant PR transcripts were detected in addition to wild-type PR. Southern blots from these experiments are illustrated in Fig. 3 .
Amplification across exons 2, 3, and 4 revealed smaller bands (Fig. 3A) , which, on the basis of size and the pattern of hybridization to oligonucleotide probes positioned in exons 2 and 3, are likely to represent variant PR transcripts from which exon 2 (⌬ 2 PR) and both exons 2 and 3 (⌬ 2ϩ3 PR) were deleted. On Southern blots, each of these variants produced only a faint signal, which was not clearly discerned in all cases. A PR variant from which exon 4 of the PR sequence had been deleted (⌬ 4 PR) was identified in 24 of the 25 cases. The identity of this species was confirmed by the pattern of differential hybridization to oligonucleotide probes; in addition, the ⌬ 4 PR variant was subcloned and sequenced from 3 tumors (data not shown). A product of approximately 600 bp was also seen in these experiments. Differential hybridization with oligonucleotides in exons 3 and 4 of PR revealed that 2 separate species were contributing to this band: a product from which exon 3 of the PR sequence was deleted (⌬ 3 PR) and a novel variant from which the first 126 bp of exon 4 were deleted (⌬ 4/2 PR; Fig. 3C ). When a fragment of PR spanning exons 5, 6, and 7 was amplified (Fig. 3B) , a product of 657 bp was identified. When this was subcloned and sequenced, it was proven to be a PR variant from which the exon 6 sequence was deleted (⌬ 6 PR). In addition, a faint band corresponding in size to a transcript lacking both exon 5 and 6 sequences (⌬ 5ϩ6 PR) was noted. No transcripts lacking exon 7 of PR were detected.
Relative expression of ER and PR alternatively spliced transcripts
When the level of expression of variant transcripts was compared semiquantitatively with that of the wild-type ER or PR transcript, it was found that for each variant there was a characteristic level of expression, and the range for the tumors examined was quite small (Table 1 ). In general, ER variant transcripts were more abundant than PR variants.
The most highly expressed species was the ⌬ 7 ER, which was detected at levels ranging from 29 -83% of wild-type ER (mean, 51%). Mean levels of expression of the other ER variants were less than 25% that of wild type. Of the PR variant transcripts, the most abundant species was the ⌬ 6 PR, which was detected in 23 of 25 tumors and had a mean level of expression of 8% that of wild-type PR. The other 2 relatively abundant PR variant species were ⌬ 4 PR and ⌬ 4/2 PR, which had mean levels of expression of 2% and 4% that of the wild type, respectively. For each alternatively spliced transcript species detected, there were individual tumors that contained high levels compared with the overall population; however, a general propensity to form alternatively spliced transcripts was not seen as these cases did not necessarily express high levels of other variant species (data not shown). , and 7 probed with PR cDNA. Wild-type PR is 788 bp in length, and a smaller product of 657 bp, representing the ⌬ 6 PR, is also seen. In a proportion of tumors a very faint band corresponding to the 513-bp ⌬ 5ϩ6 PR was seen with longer exposure of the phosphorscreen (not shown). C, Sequence spanning the site of deletion of 126 bp of the PR sequence in the ⌬ 4/2 PR variant. The sequence was derived using an antisense PR primer and therefore reads from 3Ј to 5Ј. The precise location of the splice junction in the variant is impossible to determine, as the first two nucleotides of PR exon 4 are GT, and this nucleotide combination is also present at position 2276 of the PR cDNA sequence. It is likely, however, that the variant is formed by the splicing together of the native junction at the end of exon 3 and a cryptic splice site at position 2776 (29) .
Coexpression of alternatively spliced ER and PR transcripts and expression of the estrogen-responsive proteins PR and pS2
To determine whether the expression of variant transcripts was related to markers of hormonal sensitivity in breast cancers, the profile of expression of the estrogen-responsive proteins, PR and pS2, was examined in the 35 primary breast cancer specimens ( Table 2 ). All of the tumors were ER positive by EIA, except for a single case with ER of 4 fmol/mg protein but ER positive by immunohistochemistry which was therefore included. In this small cohort there was considerable heterogeneity in the expression of the two proteins, with 51% being PR ϩ pS2 ϩ , 14% being PR Ϫ pS2 ϩ , 23% being PR ϩ pS2 Ϫ , and 11% being PR Ϫ pS2 Ϫ . Despite the heterogeneity in putative ER function evidenced by the combined PR/pS2 phenotype, a common profile of variant ER transcripts was seen in this cohort. All of the tumors contained the ⌬ 2 ER and ⌬ 7 ER, and none contained the ⌬ 3 ER and ⌬ 6 ER variants. The ⌬ 4 ER was absent from 2 cases only. The ⌬ 5 ER was present in 29 of the 35 cases. Three of the 6 cases in which the variant was not identified contained both PR and pS2; one was PR Ϫ pS2 ϩ , one was PR ϩ pS2 Ϫ , and the remaining case expressed neither protein. The distribution with respect to PR and pS2 was similar for cases that contained the ⌬ 5 ER as for those that did not. It was clear, therefore, that there was no relationship between the profile of ER variants and receptor function.
The level of expression of the most abundant variant, ⌬ 7 ER, was compared with the expression of PR and pS2. When the cases were subdivided according to the pattern of expression of PR and pS2, no relationship with the ⌬ 7 ER level was seen (by one-factor ANOVA, P ϭ 0.19; Fig. 4) .
In the subset of tumors that were PR ϩ , there was also a common profile of variant transcripts, as ⌬ 3 PR, ⌬ 4 PR, ⌬ 4/2 PR, and ⌬ 6 PR species were detected in the majority of tumors. The ⌬ 2 PR and transcripts lacking two exons (⌬ 2ϩ3 PR and ⌬ 5ϩ6 PR) were detected infrequently (Table 2) ; however, it was notable that these latter transcripts were present in very low abundance, so it cannot be excluded that failure to detect these in some tumors may be related to the limit of detection of the method.
When expression of the most abundant alternatively spliced PR transcripts (⌬ 4 PR, ⌬ 4/2 PR, and ⌬ 6 PR) was compared on the basis of pS2 positivity, no difference was noted between pS2 ϩ and pS2 Ϫ tumors (Table 2) . Percentages are given in parentheses.
Discussion
In this series of 35 ER-positive primary breast tumors, the pattern of expression of the estrogen-responsive proteins PR and pS2 revealed considerable variability in putative ER function; however, the pattern of alternative splicing of the ER transcript was uniform. All of the tumors contained the ⌬ 2 ER and ⌬ 7 ER variant transcripts, whereas ⌬ 3 ER and ⌬ 6 ER variants were not seen. The ⌬ 4 ER was absent from two cases only. The ⌬ 5 ER was detected in the majority of tumors, but there was no apparent relationship between expression of the ⌬ 5 ER and the pattern of expression of PR and pS2. There was no concordance between the small groups of cases in which ⌬ 4 ER and ⌬ 5 ER were not found. It is apparent, therefore, that there is a common profile of variant ER transcripts in breast cancer, and this feature is not related to receptor function, as revealed by the presence of estrogen-dependent end points. These data are consistent with results reported by Zhang et al. (18) .
A subset of 25 tumors from this cohort that were both ER and PR positive were examined using a similar strategy for the presence of variant PR transcripts. Multiple truncated PR transcripts were detected in all cases. PR, was very low, and it is likely therefore that their apparent absence from some cases is due to their being below the level of detection.
These data suggest that primary breast tumors are not distinguished by the profile of expression of ER or PR variant transcripts and that this feature cannot, therefore, be indicative of hormone responsiveness. Further, a general propensity for alternative splicing of ER and PR transcripts was not seen, as cases that expressed high levels of a specific variant relative to other members of the cohort did not necessarily contain high levels of others.
Alternative splicing of the primary transcript is the most likely mechanism for the formation of variant transcripts from which entire exon sequences have been deleted. With respect to both ER and PR, the multiplicity of variants detected and the distinct profiles of these indicate that the primary transcripts are subject to a number of alternative splicing events, and there are specific splice junctions that are vulnerable to this process. It is noted, for example that although exons 2, 4, 5, and 7 were commonly excluded from ER, a variant ER transcript lacking exon 6 was not detected in this series and has never been identified. Similarly for PR, deletion of exons 2, 3, 4, and 6 were observed, whereas an exon 7-deleted variant was not seen, and exon 5 was deleted only in combination with exon 6. Insight into the selection of splice sites may come from the novel PR variant ⌬ 4/2 PR that was detected in this series. This transcript is the result of deletion of 126 bp from exon 4 of the PR sequence and is likely to be formed by the splicing together of the native donor splice site from the 3Ј-end of PR exon 3 with a cryptic acceptor site within exon 4 at position 2776 (29) . It is noted that the bases bounding this cryptic splice junction conform to the acceptor splice site consensus sequence (Table 3) , suggesting that the formation of the ⌬ 4/2 PR variant may be due to the cryptic splice site successfully competing with the native sequence for recognition in the splicing reaction in a small proportion of transcripts. In the formation of others of the alternatively spliced ER and PR variants, however, the degree of conformation to the consensus sequence of splice sites that are never excluded in the formation of variant transcripts is not greater than those that are, suggesting that factors other than splice site strength are likely to determine the pattern of alternative splicing.
One of the outstanding questions pertaining to the alternatively spliced ER transcripts is to what extent these transcripts are translated into variant proteins. Despite the availability of monoclonal anti-ER antibodies directed against the N-terminus of the protein, which should be intact in the variant, and the demonstration of antibody binding to variant proteins in vitro (11, 30, 31) , studies of ER at the protein level do not readily correspond to the multitude of variant ER transcripts that have been described. There is some evidence that at least some of the proteins corresponding to alternatively spliced ER variants exist, however. Castles et al. detected a protein corresponding in size to the ⌬ 5 ER by immunoprecipitation followed by immunoblotting in the BT20 breast cancer cell line (32), and Desai et al. using an anti-⌬ 5 ER monoclonal antibody reported specific staining in frozen sections from two breast tumors (10 immunoreactive bands seen in some tumors on these blots are potential candidates (22) .
In vitro studies of variant receptor function have supported the view that these variants may impact on hormone sensitivity; however, this has not been confirmed to date by studies of clinical material. One reason for this discrepancy might be that the effects demonstrated in vitro have been in the context of much higher relative expression of the variants than are present in vivo. Wang et al. reported that cotransfection of a 20-fold excess of ⌬ 2 ER to wild-type ER in HeLa cells resulted in mild inhibition of ER function, and when ⌬ 3 ER was expressed at an equivalent level as wild-type ER, a 30% reduction in ER activity was noted (12) . With respect to PR variants, Richer et al. reported that a 10-fold excess of ⌬ 6 PR reduced the activity of PR B by 60 -70% and equimolar ⌬ 5ϩ6 PR reduced the activity of PR B by 20% and that of PR A by 65% (17) . In this study, however, the mean level of expression of ⌬ 2 ER transcript was 18% that of wild-type ER, and the mean level of expression of ⌬ 6 PR was 8% that of wild-type PR. The ⌬ 3 ER and ⌬ 5ϩ6 PR variant transcripts were barely detectable. Although results derived from RNA extracted from a tissue homogenate are likely to be a crude reflection only of events at a molecular level, the low level of relative expression of the alternatively spliced transcripts in breast tumors imply that corresponding variants would require more powerful dominant activity than has been reported to date to significantly impact on hormone sensitivity.
The most abundant variant species detected in this series was the ⌬ 7 ER, which was present at levels ranging from 29 -83% of wild-type levels. In this range of expression, an effect on ER function might be expected, as Fuqua et al. reported a 60% reduction in ER function in a yeast expression system when the ⌬ 7 ER was expressed at an equivalent level as wild-type ER (11) . In contrast to reports that the ⌬ 7 ER was more highly expressed in ER ϩ PR Ϫ tumors than ER ϩ PR ϩ cases (11, 18) , in this study the relative level of the ⌬ 7 ER could not be related to the expression of the estrogen-responsive proteins PR and pS2, and there was no evidence therefore to implicate the ⌬ 7 ER in aberrant ER function.
In summary, we have found in a series of 35 primary breast tumors that multiple alternatively spliced ER and PR transcripts coexist and that there is a common profile of these variants. This uniformity is in contrast to considerable variation in receptor levels and expression hormone-responsive markers and implies that alternative splicing of the primary transcript may not be a determinant of receptor function. 
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